|
| 36780608 | Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. | J Clin Oncol | 2023 |
| 36166093 | Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. | Clin Cancer Res | 2023 |
| 36162037 | Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). | Journal of Clinical Oncology | 2023 |
| 36282874 | Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. | Clin Cancer Res | 2023 |
| 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | J Clin Oncol | 2023 |
| 35867951 | Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. | Journal of Clinical Oncology | 2023 |
| 36400594 | Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. | Pathology | 2023 |
| 37606856 | Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. | | 2023 |
| 37951732 | Affecting change as a clinical academic. | | 2023 |
| 37845511 | Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. | | 2023 |
| 37665297 | COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. | | 2023 |
| 37827067 | Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. | | 2023 |
| 37651676 | Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. | | 2023 |
| 37910527 | Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia. | PLoS One | 2023 |
| 37808404 | Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. | | 2023 |
| 37894379 | VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-Analysis. | | 2023 |
| 37880788 | The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. | J Transl Med | 2023 |
| 37966706 | Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging. | | 2023 |
| 37789011 | Uncovering the complex relationship between balding, testosterone and skin cancers in men. | Nat Commun | 2023 |
| 37865395 | Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. | | 2023 |
| 37414216 | Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. | Ann Oncol | 2023 |
| 37348035 | Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. | J Clin Oncol | 2023 |
| 37286471 | Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma. | | 2023 |
| 36842413 | Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. | | 2023 |
| 37089863 | Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. | Cancer Res Commun | 2023 |
| 37277264 | Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. | | 2023 |
| 36895912 | Case series: Immune checkpoint inhibitor-induced transverse myelitis. | | 2023 |
| 37018924 | Efficacy of ipilimumab 3Â mg/kg following progression on low-dose ipilimumab in metastatic melanoma. | | 2023 |
| 36889810 | Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. | J Immunother Cancer | 2023 |
| 37132182 | Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. | Immunotherapy | 2023 |
| 37193799 | Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. | Nat Med | 2023 |
| 37192435 | Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. | J Clin Oncol | 2023 |
| 36627494 | Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. | Nature | 2023 |
| 36477181 | Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. | Clin Cancer Res | 2023 |
| 36934113 | The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. | | 2023 |
| 37055772 | Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. | | 2023 |
| 36736995 | IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. | | 2023 |
| 37301717 | Adjuvant therapy for stage II melanoma: the need for further studies. | | 2023 |
| 36680880 | Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. | | 2023 |
| 37167764 | Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. | Eur J Cancer | 2023 |
| 37104746 | Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. | | 2023 |
| 36926262 | Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations. | | 2023 |
| 36790412 | Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy. | Clin Cancer Res | 2023 |
| 36603931 | Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply. | | 2023 |
| 36920329 | IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. | J Exp Med | 2023 |
| 36788083 | Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets. | | 2023 |
| 36455412 | Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF wild-type melanoma progressing on prior anti-programmed death-1 therapy. | European Journal of Cancer | 2023 |
| 37535354 | Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. | | 2023 |
| 37534694 | Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose. | | 2023 |
| 37499671 | Cutaneous melanoma. | Lancet | 2023 |